Compare Synopsys, Inc. (SNPS) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Health Care Select Sector SPDR Fund — how do they compare? Synopsys, Inc. trades at $504.86 (market cap $95.39B), while Health Care Select Sector SPDR Fund trades at $170.28 (market cap $43.48B). The key difference: Synopsys, Inc. is far larger — about 2.2× Health Care Select Sector SPDR Fund's market cap, and Health Care Select Sector SPDR Fund is more actively traded (11,121,431 versus 3,374,903). Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| SNPS | XLV | |
|---|---|---|
Market Cap | $95.39B | $43.48B |
Volume | 3,374,903 | 11,121,431 |
Sector | Technology | — |
52-Week High | $534.56 | $175.68 |
52-Week Low | $367.70 | $141.95 |
Typical Hold Time | 71 Days | 100 Days |
Enterprise Value | $102.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights AI-driven partnerships with OpenAI and Amazon, boosting growth prospects. Valuation ratios are elevated, with a P/E of 86.87, reflecting high growth expectations. Analyst sentiment is overwhelmingly positive, with a consensus price target of $572.54.
The outlook for SNPS is favorable, driven by AI integration and strategic acquisitions, but risks include high valuation sensitivity and competitive pressures. Revenue growth and margin expansion from new deals present opportunities, though investors should monitor execution risks and market volatility. The stock's proximity to key resistance levels suggests potential for near-term consolidation or breakout.
XLV trades at $169.58 with a slight 0.46% daily gain amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent news highlights XLV's competitive expense ratio of 0.08% and defensive healthcare sector positioning. Options activity shows increased put volume, suggesting some investor caution despite the fund's diversification across 61 healthcare stocks.
The healthcare ETF presents a cost-effective defensive play with potential upside if political volatility subsides post-elections. Key risks include sector-specific regulatory pressures and biotech trial failures impacting holdings. Current technical weakness near support at $166 requires monitoring for potential breakdown, though the fund's low fees and broad diversification provide stability during market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
